Clinical Trials Sponsored by Kadmon Corporation, LLC

Total 141 results

Kadmon Corporation, LLC

Completed

Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy

Psoriasis Vulgaris

United States
Kadmon Corporation, LLC

Terminated

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

HER-2 Positive Breast Cancer | Metastatic Malignant Neoplasm to Brain

United States
Kadmon Corporation, LLC

Completed

A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris

Psoriasis Vulgaris

United States
Kadmon Corporation, LLC

Completed

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

Chronic Plaque Psoriasis

United States
Kadmon Corporation, LLC

Completed

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Glioblastoma | Brain Tumor | Recurrent Glioblastoma

United States
Kadmon Corporation, LLC

Completed

A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Kadmon Corporation, LLC

Terminated

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States
Kadmon Corporation, LLC

Completed

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

Cancer

United States
Kadmon Corporation, LLC

Completed

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Polycystic Kidney, Autosomal Recessive

United States
Kadmon Corporation, LLC

Completed

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Non-Small Cell Lung Cancer | Brain Metastases | Leptomeningeal Metastases

United States
Kadmon Corporation, LLC

Completed

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Carcinoma, Non-Small-Cell Lung

United States
Kadmon Corporation, LLC

Completed

Study of XL647 in Subjects With Non-Small-Cell Lung Cancer

Non-small-cell Lung Cancer

United States
Kadmon Corporation, LLC

Completed

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Cancer

United States
Kadmon Corporation, LLC

Terminated

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States
Kadmon Corporation, LLC

Withdrawn

Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C (REACHSVR)

Hepatitis C
Kadmon Corporation, LLC

Terminated

Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin (ENHANCE)

Hepatitis C

United States
Kadmon Corporation, LLC
Quotient Sciences

Completed

Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025 (KD025-108)

Fibrosis | Autoimmune Diseases

United Kingdom
Kadmon Corporation, LLC
Quotient Clinical

Completed

Bioavailability of Belumosudil (KD025) in Healthy Male Subjects

Bioavailability

United Kingdom
Kadmon Corporation, LLC
Quotient Sciences

Completed

A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

Healthy Volunteers

United Kingdom
Kadmon Corporation, LLC
Quotient Sciences

Completed

Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers

Autoimmune Diseases | Drug-drug Interaction | Fibrotic Disease

United Kingdom
Edward Chu, MD
Kadmon Corporation, LLC

Completed

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

United States
Bioventus LLC
Seikagaku Corporation

Completed

Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA

Osteoarthritis

United States
Pharmacyclics LLC.
Celgene Corporation

Terminated

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Czechia, Germany, Greece
Clinyx, LLC
Volcano Corporation

Completed

Performing Fractional Flow Reserve Without Anticoagulation During Diagnostic Catheterization

Coronary Artery Disease
Pharmacyclics LLC.
Celgene Corporation

Completed

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma Refractory | Diffuse Large B Cell Lymphoma Relapsed

United States
PrECOG, LLC.
Celgene Corporation

Completed

Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma (PrE0204)

Cholangiocarcinoma

United States, Austria
Verily Life Sciences LLC
The Emmes Company, LLC; Optos, PLC; Google LLC.; Nikon Corporation

Completed

ARDA Software for the Detection of mtmDR

Diabetic Retinopathy

United States
Innovis LLC
Exact Sciences Corporation

Recruiting

Vaginal Fluid Collection for Detection of Endometrial Cancer

Endometrial Cancer

United States
Innovis LLC
Exact Sciences Corporation

Recruiting

Stool Sample Collection Study

Colorectal Cancer

United States
NaviFUS Corporation
NaviFUS US LLC

Not yet recruiting

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Glioma | Neoplasms | Glioblastoma | Neoplasms, Nerve Tissue | Brain Tumor | Glioblastoma Multiforme

United States
MiniStim LLC

Recruiting

Clinical Trial of the MiniStim PNS for Knee Pain- "FLEX" Study

Chronic Knee Pain

United States
Pharmacyclics LLC.
Janssen Research & Development, LLC; Celgene Corporation

Completed

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States, United Kingdom, Belgium, Germany
LMC Diabetes & Endocrinology Ltd.
Merck Sharp & Dohme LLC; Syreon Corporation

Withdrawn

Approaches To Therapy Escalation In T2D (ATTACC)

Type2 Diabetes
Incyte Corporation
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Head and Neck Cancer

Canada, Spain, Korea, Republic of, United States, Austria, Japan, United Kingdom, Taiwan, Italy, Hungary, Australia, Turkey, Poland, Portugal
SCRI Development Innovations, LLC
Incyte Corporation

Terminated

A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft-versus-host-disease

United States
Qure Healthcare, LLC
Venn Biosciences Corporation

Withdrawn

Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test

Non Small Cell Lung Cancer
Honeybrains Biotech LLC
Cognitive Research Corporation

Completed

Safety and Efficacy of HB-1 for Panic Disorder

Panic Disorder

United States
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

UC (Urothelial Cancer)

United States, Spain, Hungary, Israel, United Kingdom, Korea, Republic of, Taiwan, Denmark, France, Netherlands, Italy, Canada, Japan, Turkey, Germany, Ireland, Australia, Russian Federation
SCRI Development Innovations, LLC
Celgene Corporation

Completed

Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

Breast Cancer

United States
BriaCell Therapeutics Corporation
Cancer Insight, LLC

Completed

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

Breast Neoplasm | Breastcancer

United States
SCRI Development Innovations, LLC
Celgene Corporation

Completed

Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas

Metastatic Pancreatic Cancer

United States
SCRI Development Innovations, LLC
Celgene Corporation

Completed

Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer

Metastatic Breast Cancer

United States
SCRI Development Innovations, LLC
Celgene Corporation

Terminated

Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer

Breast Cancer
Incyte Corporation
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Renal Cell Carcinoma (RCC)

Canada, France, United States, Spain, United Kingdom, Italy, Taiwan, Australia, Norway, Korea, Republic of, Germany, Russian Federation, Japan, Brazil, Turkey, Ukraine, Hungary, New Zealand, Chile, Ireland
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Lung Cancer

United States, Hungary, Spain, Ireland, Italy, Taiwan, Korea, Republic of, United Kingdom, Turkey, Canada, Israel, Australia, Mexico, Russian Federation
Adelphi Values LLC
Blueprint Medicines Corporation

Completed

Patient-Reported Outcome Questionnaire for Systemic Mastocytosis

Mast Cell Leukemia (MCL) | Aggressive Systemic Mastocytosis (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | Smoldering Systemic Mastocytosis (SSM) | Indolent Systemic Mastocytosis (ISM) ISM Subgroup Fully Recruited

United States
Janssen Research & Development, LLC
Yuhan Corporation

Completed

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United Kingdom, United States, Spain
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Melanoma | Lymphoma | Head and Neck Cancer | Gastric Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Lung Cancer | Bladder Cancer | Endometrial Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | UC (Urothelial Cancer) | Microsatellite-instability (MSI) High Colorectal...

United States
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Lung Cancer

Spain, Ireland, Canada, Denmark, Japan, Israel, Korea, Republic of, Malaysia, United States, Turkey, Italy, Ukraine, Switzerland, Russian Federation, Poland, Australia, Estonia, United Kingdom
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

UC (Urothelial Cancer)

United States, France, Belgium, Israel, Spain, United Kingdom, Korea, Republic of, Taiwan, Australia, Netherlands, Japan, Germany, Ukraine, Canada, Ireland, Italy, Poland, Russian Federation

Clinical Trials Sponsored by Kadmon Corporation, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations